Medegen extends distribution horizons with Bard deal
This article was originally published in Clinica
Infusion therapy specialist Medegen will make its MaxPlus Clear needle-less access connector available with CR Bard’s inserted central catheter (PICC) kits, after the two firms came together in a co-marketing deal. The agreement, of which full financial details were not disclosed, will see the MaxPlus Clear included in products such as the Bard PowerPICC Solo, thus extending Medegen’s distribution reach. The MaxPlus Clear is manufactured by Medegen’s Maximus subsidiary and is claimed to be “the first and only positive displacement connector that features complete visualisation of the fluid path, which is shown to enhance patient care, leading to lower bloodstream infection and occlusion rates,” according to Ontario, California-based Medegen.